Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI)’s traded shares stood at 5.33 million during the latest session, with the company’s beta value hitting 0.38. At the last check today, the stock’s price was $0.93, to imply a decrease of -16.38% or -$0.18 in intraday trading. The BCLI share’s 52-week high remains $10.05, putting it -980.65% down since that peak but still an impressive -7.53% since price per share fell to its 52-week low of $1.00. The company has a valuation of $6.08M, with an average of 40780.0 shares in intraday trading volume over the past 10 days and average of 41.16K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Brainstorm Cell Therapeutics, Inc (BCLI), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give BCLI a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.97.
Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI) trade information
After registering a -16.38% downside in the latest session, Brainstorm Cell Therapeutics, Inc (BCLI) has traded red over the past five days. The 5-day price performance for the stock is -24.23%, and -40.64% over 30 days. With these gigs, the year-to-date price performance is -58.94%. Short interest in Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI) saw shorts transact 0.12 million shares and set a 4.54 days time to cover.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 32.00% for the past 5-year period. While 2025 is set for a 4.33% return in earnings, projections for the next 5 years are at 27.78% annually.
BCLI Dividends
Brainstorm Cell Therapeutics, Inc has its next earnings report out on 2025-Mar-30. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI)’s Major holders
Brainstorm Cell Therapeutics, Inc insiders hold 20.80% of total outstanding shares, with institutional holders owning 12.49% of the shares at 15.78% float percentage. In total, 12.49% institutions holds shares in the company, led by ARMISTICE CAPITAL, LLC. As of 2024-06-30, the company held over 7.92 million shares (or 11.1179% of shares), all amounting to roughly $2.68 million.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 1.51 million shares, or about 2.3334% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $0.51 million.
We also have VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Fidelity Concord Street Trust-Fidelity Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Brainstorm Cell Therapeutics, Inc (BCLI) shares. Going by data provided on Dec 31, 2024 , VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund holds roughly 50.72 shares. This is just over 0.78% of the total shares, with a market valuation of $44869.0. Data from the same date shows that the other fund manager holds a little less at 27.43, or 0.42% of the shares, all valued at about 24262.0.
